Successful antiangiogenic therapy for neuroblastoma with thalidomide

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5321-5324

  Gesundheit, Benjamin ^a   Moser, Asher ^b   Or, Reuven ^a   Klement, Giannoula ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ISOTRETINOIN; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANAMNESIS; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; FLOW CYTOMETRY; FOLLOW UP; GENE DELETION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; ONCOGENE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; CHILD, PRESCHOOL; HUMANS; MALE; NEUROBLASTOMA; THALIDOMIDE;

EID: 36849052815     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.3331     Document Type: Article

References (23)

1. Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279, 1999
2. Finklestein JZ, Klemperer MR, Evans A, et al: Multiagent chemotherapy for children with metastatic neuroblastoma: A report from Childrens' Cancer Study Group. Med Ped Oncol 6:179-188, 1979
3. Weinstein JL, Katzenstein HM, Cohn SL: Advances in the diagnosis and treatment of neuroblastoma. Oncologist 8:278-292, 2003
4. Castleberry RP, Cantor AB, Green AA, et al: Phase II investigational window using carboplatin, ioroplatin, ifosfamide, and iepirubicin in children with untreatee disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 12:1616-1620, 1994
5. Cheung NV, Heller G: Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058, 1991
6. Ladenstein R, Philip T, Lasset C, et al: Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16:953-965, 1998
7. Keshelava N, Seeger RC, Groshen S, et al: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 58:5396-5405, 1998
8. Hartmann O, Berthold F: Treatment of advanced neuroblastoma: The European Experience, in Brodeur GM, Sawada T, Tsuchida Y, et al (eds): Neuroblastoma. Amsterdam, the Netherlands, Elsevier Science, 2000, pp 437-452
9. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13- cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173, 1999
10. Kushner BH, Cheung NK, Kramer K, et al: Neuroblastoma and treatmentrelated myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 16:3880-3889, 1998
11. Brignole C, Marimpietri D, Pastorino F, et al: Effect of bortezomib on human neuroblastoma cell growth, apoptosis and angiogenesis. J Natl Cancer Inst 98:1142-1157, 2006
12. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med 285:1182-1186, 1971
13. Ribatti D, Vacca A, Dammacco F: The role of the vascular phase in solid tumor growth: A historical review. Neoplasia 1:293-302, 1999
14. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 21:505-515, 2000
15. Rajkumar SV, Mesa R, Tefferi A: A review of angiogenesis and antiangiogenic therapy in hematologic malignancies. J Hematother Stem Cell Res 11:33-47, 2002
16. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
17. Weber D, Rankin K, Gavino M, et al: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21:16-19, 2003
18. Reference deleted.
19. Meitar D, Crawford SE, Rademaker AW, et al: Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405-414, 1996
20. Katzenstein HM, Salwen HR, Nguyen NN, et al: Antiangiogenic therapy inhibitis human neuroblastoma growth. Med Pediatr Oncol 36:190-193, 2001
21. Shusterman S, Grupp SA, Barr R, et al: The angiogenesis inhibitor TPN-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7:977-984, 2001
22. Avramovich Y, Amit T, Youdim MB: Non-steroidal anti-inflammatory drugs stimulate secretion of non-amyloidogenic precursor protein. J Biol Chem 277: 31466-31473, 2002
23. Brignole C, Marimpietri D, Pastorino F, et al: Bortezomib on human neuroblastoma cell growth, apoptosis and angiogenesis. J Natl Cancer Inst 98:1142-1157, 2006